Active, Not Recruiting
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05438420
- Conditions
- Cervical Cancer, Digestive System Diseases, Digestive System Neoplasms, +25 more
- Locations
-
- University of Southern California Los Angeles, California, United States
- Norton Cancer Institute Louisville, Kentucky, United States
- CHA Bundang Medical Center Seongnam-si, South Korea
- Asan Medical Center Seoul, South Korea